Literature DB >> 19432547

Evaluation of the pathogenesis of decreasing CD4(+) T cell counts in human immunodeficiency virus type 1-infected patients receiving successfully suppressive antiretroviral therapy.

Elizabeth Nies-Kraske1, Timothy W Schacker, David Condoluci, Jan Orenstein, Jason Brenchley, Cecil Fox, Marybeth Daucher, Robin Dewar, Elizabeth Urban, Brenna Hill, Javier Guenaga, Shelley Hoover, Frank Maldarelli, Claire W Hallahan, Judith Horn, Shyamasundaran Kottilil, Tae-Wook Chun, Marlene Folino, Sara Palmer, Ann Wiegand, M Angeline O'Shea, Julia A Metcalf, Daniel C Douek, John Coffin, Ashley Haase, Anthony S Fauci, Mark Dybul.   

Abstract

Most human immunodeficiency virus (HIV)-infected individuals experience increases in peripheral CD4(+) T cell counts with suppressive antiretroviral therapy (ART) that achieves plasma HIV RNA levels that are less than the limit of detection. However, some individuals experience decreasing CD4(+) T cell counts despite suppression of plasma viremia. We evaluated 4 patients with a history of CD4(+) T cell decline despite successfully suppressive ART, from a median of 719 cells/mm(3) (range, 360-1141 cells/mm(3)) to 227 cells/mm(3) (range, 174-311 cells/mm(3)) over a period of 18-24 months; 3 of the patients were receiving tenofovir and didanosine, which may have contributed to this decrease. There was no evidence of HIV replication, nor of antiretroviral drug resistance in the blood or lymphoid tissue, or increased proliferation or decreased thymic production of naive CD4(+) T cells. All 4 patients had significant fibrosis of the T cell zone of lymphoid tissue, which appeared to be an important factor in the failure to reconstitute T cells.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19432547      PMCID: PMC4826569          DOI: 10.1086/598980

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  48 in total

Review 1.  Modelling viral and immune system dynamics.

Authors:  Alan S Perelson
Journal:  Nat Rev Immunol       Date:  2002-01       Impact factor: 53.106

2.  Evaluation of lymph node virus burden in human immunodeficiency virus-infected patients receiving efavirenz-based protease inhibitor--sparing highly active antiretroviral therapy.

Authors:  M Dybul; T W Chun; D J Ward; K Hertogs; B Larder; C H Fox; J M Orenstein; B F Baird; Y Li; L G Green; D Engel; S Liu; J M Mican; A S Fauci
Journal:  J Infect Dis       Date:  2000-04       Impact factor: 5.226

3.  Proviral HIV-1 DNA in subjects followed since primary HIV-1 infection who suppress plasma viral load after one year of highly active antiretroviral therapy.

Authors:  N Ngo-Giang-Huong; C Deveau; I Da Silva; I Pellegrin; A Venet; M Harzic; M Sinet; J F Delfraissy; L Meyer; C Goujard; C Rouzioux
Journal:  AIDS       Date:  2001-04-13       Impact factor: 4.177

4.  Cell-associated HIV-1 RNA in blood as indicator of virus load in lymph nodes. The Swiss HIV Cohort Study.

Authors:  S Yerly; O T Rutschmann; M Opravil; F Marchal; B Hirschel; L Perrin
Journal:  J Infect Dis       Date:  1999-09       Impact factor: 5.226

5.  Reduction of HIV-1 in blood and lymph nodes following potent antiretroviral therapy and the virologic correlates of treatment failure.

Authors:  J K Wong; H F Günthard; D V Havlir; Z Q Zhang; A T Haase; C C Ignacio; S Kwok; E Emini; D D Richman
Journal:  Proc Natl Acad Sci U S A       Date:  1997-11-11       Impact factor: 11.205

6.  Antiretroviral effect of zidovudine-didanosine combination on blood and lymph nodes.

Authors:  A Lafeuillade; C Tamalet; C Poggi; P Pellegrino; C Tourres; J Izopet
Journal:  AIDS       Date:  1997-01       Impact factor: 4.177

7.  A proof-of-concept study of short-cycle intermittent antiretroviral therapy with a once-daily regimen of didanosine, lamivudine, and efavirenz for the treatment of chronic HIV infection.

Authors:  Mark Dybul; Elizabeth Nies-Kraske; Robin Dewar; Frank Maldarelli; Claire W Hallahan; Marybeth Daucher; Stephen C Piscitelli; Linda Ehler; Ann Weigand; Sarah Palmer; Julia A Metcalf; Richard T Davey; Diane M Rock Kress; April Powers; Ingrid Beck; Lisa Frenkel; Michael Baseler; John Coffin; Anthony S Fauci
Journal:  J Infect Dis       Date:  2004-05-10       Impact factor: 5.226

8.  Changes in thymic function with age and during the treatment of HIV infection.

Authors:  D C Douek; R D McFarland; P H Keiser; E A Gage; J M Massey; B F Haynes; M A Polis; A T Haase; M B Feinberg; J L Sullivan; B D Jamieson; J A Zack; L J Picker; R A Koup
Journal:  Nature       Date:  1998-12-17       Impact factor: 49.962

9.  Functional genomic analysis of the response of HIV-1-infected lymphatic tissue to antiretroviral therapy.

Authors:  Qingsheng Li; Timothy Schacker; John Carlis; Gregory Beilman; Phuong Nguyen; Ashley T Haase
Journal:  J Infect Dis       Date:  2004-02-05       Impact factor: 5.226

10.  Collagen deposition in HIV-1 infected lymphatic tissues and T cell homeostasis.

Authors:  Timothy W Schacker; Phuong L Nguyen; Gregory J Beilman; Steven Wolinsky; Matthew Larson; Cavan Reilly; Ashley T Haase
Journal:  J Clin Invest       Date:  2002-10       Impact factor: 14.808

View more
  11 in total

1.  Telmisartan Therapy Does Not Improve Lymph Node or Adipose Tissue Fibrosis More Than Continued Antiretroviral Therapy Alone.

Authors:  Netanya S Utay; Douglas W Kitch; Eunice Yeh; Carl J Fichtenbaum; Michael M Lederman; Jacob D Estes; Claire Deleage; Clara Magyar; Scott D Nelson; Karen L Klingman; Barbara Bastow; Amneris E Luque; Grace A McComsey; Daniel C Douek; Judith S Currier; Jordan E Lake
Journal:  J Infect Dis       Date:  2018-05-05       Impact factor: 5.226

2.  Combining Cell and Gene Therapy in an Effort to Eradicate HIV.

Authors:  Thor A Wagner
Journal:  AIDS Patient Care STDS       Date:  2016-12       Impact factor: 5.078

3.  Role of intestinal myofibroblasts in HIV-associated intestinal collagen deposition and immune reconstitution following combination antiretroviral therapy.

Authors:  David M Asmuth; Irina V Pinchuk; Jian Wu; Gracie Vargas; Xiaoli Chen; Surinder Mann; Anthony Albanese; Zhong-Min Ma; Ramez Saroufeem; Gregory P Melcher; Paolo Troia-Cancio; Natalie J Torok; Christopher J Miller; Don W Powell
Journal:  AIDS       Date:  2015-05-15       Impact factor: 4.177

Review 4.  Cardiovascular Disease, Statins, and HIV.

Authors:  Allison Ross Eckard; Eric G Meissner; Inderjit Singh; Grace A McComsey
Journal:  J Infect Dis       Date:  2016-10-01       Impact factor: 5.226

5.  Alternative serotype adenovirus vaccine vectors elicit memory T cells with enhanced anamnestic capacity compared to Ad5 vectors.

Authors:  Pablo Penaloza-MacMaster; Nicholas M Provine; Joshua Ra; Erica N Borducchi; Anna McNally; Nathaniel L Simmons; Mark J Iampietro; Dan H Barouch
Journal:  J Virol       Date:  2012-11-14       Impact factor: 5.103

Review 6.  Pathobiology of HIV/SIV-associated changes in secondary lymphoid tissues.

Authors:  Jacob D Estes
Journal:  Immunol Rev       Date:  2013-07       Impact factor: 12.988

7.  Factors predicting discordant virological and immunological responses to antiretroviral therapy in HIV-1 clade C infected Zulu/Xhosa in South Africa.

Authors:  Boris Julg; Danielle Poole; Musie Ghebremichael; Carmen Castilla; Marcus Altfeld; Henry Sunpath; Richard A Murphy; Bruce D Walker
Journal:  PLoS One       Date:  2012-02-14       Impact factor: 3.240

8.  Factors related to changes in CD4+ T-cell counts over time in patients living with HIV/AIDS: a multilevel analysis.

Authors:  Ulisses Ramos Montarroyos; Demócrito Barros Miranda-Filho; Cibele Comini César; Wayner Vieira Souza; Heloisa Ramos Lacerda; Maria de Fátima Pessoa Militão Albuquerque; Mariana Freitas Aguiar; Ricardo Arraes de Alencar Ximenes
Journal:  PLoS One       Date:  2014-02-05       Impact factor: 3.240

9.  Immuno-virological discordance and the risk of non-AIDS and AIDS events in a large observational cohort of HIV-patients in Europe.

Authors:  Alexander Zoufaly; Alessandro Cozzi-Lepri; Joanne Reekie; Ole Kirk; Jens Lundgren; Peter Reiss; Djordje Jevtovic; Ladislav Machala; Robert Zangerle; Amanda Mocroft; Jan Van Lunzen
Journal:  PLoS One       Date:  2014-01-31       Impact factor: 3.240

10.  Circulating biomarkers of immune activation distinguish viral suppression from nonsuppression in HAART-treated patients with advanced HIV-1 subtype C infection.

Authors:  Glen Malherbe; Helen C Steel; Sharon Cassol; Tulio de Oliveira; Christopher J Seebregts; Ronald Anderson; Edana Cassol; Theresa M Rossouw
Journal:  Mediators Inflamm       Date:  2014-04-06       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.